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Inhibition of a single transduction pathway is often inefficient due to activation of alternative signalling. The mammalian target of
rapamycin (mTOR) is a key intracellular kinase integrating proliferation, survival and angiogenic pathways and has been implicated in
the resistance to EGFR inhibitors. Thus, mTOR blockade is pursued to interfere at multiple levels with tumour growth. We used
everolimus (RAD001) to inhibit mTOR, alone or in combination with anti-EGFR drugs gefitinib or cetuximab, on human cancer cell
lines sensitive and resistant to EGFR inhibitors, both in vitro and in vivo. We demonstrated that everolimus is active against EGFR-
resistant cancer cell lines and partially restores the ability of EGFR inhibitors to inhibit growth and survival. Everolimus reduces the
expression of EGFR-related signalling effectors and VEGF production, inhibiting proliferation and capillary tube formation of
endothelial cells, both alone and in combination with gefitinib. Finally, combination of everolimus and gefitinib inhibits growth of GEO
and GEO-GR (gefitinib resistant) colon cancer xenografts, activation of signalling proteins and VEGF secretion. Targeting mTOR
pathway with everolimus overcomes resistance to EGFR inhibitors and produces a cooperative effect with EGFR inhibitors, providing
a valid therapeutic strategy to be tested in a clinical setting.
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The mammalian target of rapamycin (mTOR), also known as
FKBP12 rapamycin-associated protein, rapamycin target or
sirolimus effector protein, is a serine/threonine-specific kinase
responsible for mitogen-induced cell proliferation/survival signal-
ling (Bjornsti and Houghton, 2004; Abraham and Gibbons, 2007).
In mammalian cells, mTOR signalling depends on signal
transmission through the phosphoinositide 3-kinase (PI3K)/Akt
pathway. Activated Akt phosphorylates TSC2, a component of
tuberous sclerosis complexes 1 and 2, sensitive to nutrient status,
and favours mTOR activity (Manning et al, 2002; Zhang et al,
2003). An important function of mTOR is the translation control
via activation of ribosomal p70S6 kinase (S6K1) and suppression
of 4E-BPs, resulting in enhanced translation of mRNAs encoding
cell-cycle regulators and promotion of G1–S cell-cycle transition
(Schmelzle and Hall, 2000; Bjornsti and Houghton, 2004). The
mammalian target of rapamycin signalling is dependent on insulin,
growth factors, and nutrition status, and nutrient deficiency leads
to mTOR inhibition.
Mammalian target of rapamycin is an essential part of tumour
growth being capable of integrating proliferative, antiapoptotic
and angiogenic signalling by connecting VEGF, hypoxia-inducible
factor 1 (HIF-1) and HER family receptors. VEGF is a potent
promoter of angiogenesis, and its overexpression is associated with
tumour progression and poor clinical outcome. Hypoxia-inducible
factor 1, a heterodimeric protein consisting of HIF-1a and HIF-1b,
controls the transcription of genes involved in cell proliferation/
survival, invasion/metastasis and angiogenesis, including VEGF.
Hypoxia-inducible factor 1 is degraded through ubiquitylation
involving the von Hippel–Lindau tumour-suppressor protein,
whose loss of function, detected in renal cancer and neuro-
endocrine tumours, impairs HIF-1a degradation and favours the
stimulation of mTOR signalling (Melillo, 2007). Finally, it has been
reported that HER2 activation in normoxic cells increases HIF-1a
via PI3K, Akt and mTOR (Laughner et al, 2001), and that EGF
induces HIF-1a, which can be prevented by using mTOR inhibitors
under both normoxic and hypoxic conditions (Phillips et al, 2005).
Taken together, these studies demonstrate that mTOR is a positive
regulator of HIF-1a translation and an inducer of HIF-1/VEGF-
dependent angiogenesis. In addition, signalling through mTOR is
stimulated by defects in the pathway components upstream of
mTOR, such as growth factor receptors, PI3K, Akt, PTEN, TSC1/
TSC2, or by stimulation of PI3K by effectors of the mutant Ras/
Raf/MAPK pathway (Bjornsti and Houghton, 2004).
In view of the above-mentioned facts, several mTOR inhibitors
rapamycin-analogues have been developed, including temsirolimus
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s(CCI-779), everolimus (RAD001) and AP23573 (Hidalgo and
Rowinsky, 2000; Rowinsky, 2004). Clinical studies have been very
encouraging in renal cell cancer. In a multicenter phase 3 trial,
temsirolimus improved overall survival in metastatic renal-cell
carcinoma patients with poor prognostic score, as compared with
IFN-a; however, the addition of temsirolimus to IFN did not improve
survival (Hudes et al, 2007). The potential efficacy of these new
agents is now under evaluation in patients with other solid tumours
(Janus et al, 2005; Smolewski, 2006; Fouladi et al, 2007).
Everolimus (40-O-(2-hydroxyethyl)-rapamycin) is an orally
bioavailable derivative of rapamycin under clinical evaluation in
different types of cancer (Boulay et al, 2004), including renal cell
cancer and endometrial cancer (Sansal and Sellers, 2004). More-
over, everolimus in combination with imatinib mesylate is under
study in patients with gastrointestinal stromal tumours (Van
Oosterom et al, 2004). Phase I/II trials of everolimus in
combination with erlotinib, in patients with metastatic breast
cancer and advanced NSCLC are currently undergoing.
EGFR is a major transducer of mitogenic signals involved in
cancer pathogenesis and progression (Citri and Yarden, 2006)
upstream of mTOR and an important target for anticancer therapy
(Baselga and Arteaga, 2005; Hynes and Lane, 2005; Mendelsohn
and Baselga, 2006). Several anti-EGFR drugs, such as monoclonal
antibodies directed against the extracellular domain and small
molecule inhibitors of the receptor-associated tyrosine kinase,
have been approved for clinical use (Cunningham et al, 2004;
Bezjak et al, 2006). However, a relevant percentage of patients
treated with these drugs has no clinical benefit or incurs in the
development of acquired resistance. Constitutive and acquired
resistance to EGFR inhibitors in a large number of patients is a
relevant clinical problem. Frequently, activation of signalling
pathways downstream or alternative to EGFR may be responsible
for the development of resistance to these inhibitors (Sansal and
Sellers, 2004). We, and others, have previously shown that colon
tumours that acquire resistance to anti-EGFR drugs cetuximab and
gefitinib overexpress Akt and VEGF, which act as the escape
pathways to overcome the EGFR blockade (Viloria-Petit et al, 2001;
Ciardiello et al, 2004; Bianco et al, 2005). As mentioned above, the
PI3K-AKT pathway connects EGFR and mTOR.
The link between HIF-1 and EGF and the reported ability of
mTOR inhibitors rapamycin and everolimus to reduce VEGF
secretion in vitro and in vivo, renders mTOR inhibitors potentially
effective against cancer cells resistant to EGFR inhibitors (Viloria-
Petit et al, 2001; Ciardiello et al, 2004; Bianco et al, 2005). In
addition, targeting together mTOR and EGFR might cause a more
profound effect on tumour growth control compared with a single
agent (Hynes and Lane, 2005).
In this study, we have evaluated (1) the antitumour effect of
everolimus on different human cancer cell lines, sensitive or
resistant to EGFR inhibitors, in vitro and in nude mice; (2) the
possibility to restore sensitivity to EGFR inhibitors, using
everolimus in combination with gefitinib or cetuximab; (3) the
effect of treatment on signalling pathways and VEGF.
MATERIALS AND METHODS
Drugs
Everolimus, gefitinib and cetuximab were provided by Novartis
International AG (Basel, Switzerland), Dr Anderson Ryan (As-
traZeneca Pharmaceuticals, Macclesfield, UK) and ImClone
Systems (New York, NY, USA).
Cell lines
Human GEO colon, PC3 prostate and MDA-MB-468 breast cancer
cells were obtained from the American Type Culture Collection
(Manassas, VA, USA). GEO-CR (cetuximab resistant), GEO-GR
and PC3-GR (gefitinib resistant) cells were established as described
previously (Ciardiello et al, 2004).
Growth in soft agar
Cells (10
4 cells per well) were suspended in 0.3% Difco Noble agar
(Difco, Detroit, MI, USA) in culture medium, layered over 0.8%
agar medium base layer in 24-well plates (Becton Dickinson,
Lincoln Park, NJ, USA) and treated with gefitinib, cetuximab or
everolimus. After 10–14 days, cells were stained and colonies up to
0.05mm were counted (Ciardiello et al, 2004).
Cell-survival assay
Cells were grown in 24-well plates in the presence of everolimus
(1nM to 1mM), gefitinib (1 or 5mM) or their combination. After
removing supernatant, 1mgml
 1 of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT, Sigma, Milan, Italy)
solution in medium was added to each well. After adding
isopropanol, absorbance was measured at 570nm.
Western blot analysis
Total cell lysates were obtained from homogenised tumour
specimens or from cells. Protein extracts resolved by a 4–20%
SDS-PAGE were probed with different antibodies: anti-Akt, anti-
phospho (Ser473)-Akt (Cell Signaling, Beverly, MA, USA); anti-
ERK 1/2, anti-phospho-ERK 1/2 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA); anti-S6K1, anti-phospho S6K1, anti-VEGF (Santa
Cruz Biotechnology); anti-actin (Sigma-Aldrich, Milan, Italy).
Immunoreactive proteins were visualised by enhanced chemi-
luminescence (Amersham International, London, UK) (Ciardiello
et al, 2004).
ELISA assay
VEGF concentrations in conditioned media, total cell lysates from
homogenised tumour specimens and serum of sacrificed mice were
determined by ELISA (Guba et al, 2002). The absorbance was
measured at 490nm on a microplate reader (Bio-Rad, Hercules,
CA, USA) and VEGF concentrations were determined using linear
regression analysis.
Xenografts in nude mice
Balb/cAnNCrlBR athymic (nuþ/nuþ) mice (Charles River
Laboratories, Milan, Italy) were maintained in accordance with
institutional guidelines of the University of Naples Animal Care
Committee and Declaration of Helsinki. GEO and GEO-GR cells
(10
7 cells per mice) resuspended in Matrigel (Collaborative
Biomedical Products, Bedford, MA, USA) were injected subcuta-
neously. After 7 days, groups of 10 mice were randomised to
receive treatments: intraperitoneal gefitinib, 100mgkg
 1, three
times a week for 3 weeks; everolimus (by gavage), 5mgkg
 1, three
times a week for 3 weeks; or their combination, on days 7–11, 14–
18 and 21–25. Tumour volume was measured using the formula
p/6 larger diameter (smaller diameter)
2 (Ciardiello et al, 2004).
Two mice were sacrificed on day 25 for biochemical analysis.
Vascular endothelial cell capillary tube and network
formation
Matrigel was diluted in DMEM, added into a 30-mm culture dish
and incubated at 371C for 30min; then HUVECs (4 10
5) in RPMI
medium were added in each dish, in presence of everolimus 0.1mM,
gefitinib 5mM or the combination. The positive control was
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 1 (R&D Systems, Minneapolis, MN,
USA). Pictures were taken at 0 and 24h.
Statistical analysis
The Student’s t-test and the Mantel–Cox log-rank test were used to
evaluate the statistical significance of the results. All P-values were
two-sided. Analyses were performed with the BMDP New System
statistical package version 1.0 for Microsoft Windows (BMDP
Statistical Software, Los Angeles, CA, USA).
RESULTS
Everolimus is active in cancer cell lines resistant to
gefitinib and cetuximab and partially restores sensitivity to
these EGFR inhibitors
To evaluate the effect of everolimus on cancer cell growth, we have
performed a soft agar assay on different cancer cells. Wild-type
human colon cancer GEO cells are sensitive to both cetuximab and
gefitinib, with an IC50 of less than 0.5mgml
 1 and 0.5mM,
respectively. Wild-type human prostate cancer PC3 cells demon-
strate the same pattern of sensitivity to gefitinib, but are resistant
to cetuximab at doses up to 20mgml
 1. GEO-CR, GEO-GR and
PC3-GR human cancer cell lines were established in vitro from
GEO or PC3 tumours treated continuously for 16 weeks with either
gefitinib or cetuximab. These derivative cell lines are resistant to
cetuximab and gefitinib up to doses of 80mgml
 1 and 20mM,
respectively (data not shown). MDA-468 human breast cancer cells
exhibit low sensitivity to gefitinib (Bianco et al, 2003) and
resistance to cetuximab up to the dose of 80mgml
 1 (data not
shown). This constitutive resistant phenotype is associated with
PI3-K/Akt hyperactivity, in turn related to mutation of the
phosphatase and tensin homologue (PTEN) gene (Bianco et al,
2003). Despite similar sensitivity to gefitinib, GEO cells have a
functional wild-type PTEN gene, whereas PC3 have a deleted
PTEN. However, western blot analysis of GEO-CR, GEO-GR and
PC3-GR cells did not reveal any differences in PTEN expression
(data not shown).
Regardless of the degree of sensitivity to EGFR inhibitors and
PTEN status, everolimus caused an efficient dose-dependent
inhibition of soft agar growth in all cell lines, with an IC50 ranging
between 1 and 5mM, (Figure 1A). To evaluate the everolimus
potential to restore sensitivity to gefitinib and cetuximab in cancer
cell lines resistant to these anti-EGFR drugs, we performed a soft
agar assay on cells treated with doses of cetuximab or gefitinib
ranging from 0.1 to 1mgml
 1 and from 0.1 to 1mM, respectively, in
presence of everolimus 0.1mM. Wild-type GEO cells showed a
reduction of cetuximab IC50 from 0.5 to 0.2mgml
 1 and gefitinib
IC50 from 0.5 to 0.2mM. Wild-type PC3 cells showed a reduction of
gefitinib IC50 from 0.5 to 0.2mM, and they became sensitive to
cetuximab (IC50 0.8mgml
 1). In all the resistant cell lines,
everolimus in combination with cetuximab or with gefitinib
restored dose-dependent growth inhibition induced by anti-EGFR
drugs (Figure 1B and C).
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Figure 1 (A) Cells were treated with everolimus (0.01–20mM). (B and C) Cells were treated with cetuximab (0.1–1mgml
 1), and gefitinib (0.1–1mM),
in presence of everolimus, 0.1mM.( D) Western blotting on total cell lysates from cells treated with 1mM gefitinib, 1mgml
 1 cetuximab or 0.1mM everolimus.
Lane 1: untreated control; lane 2: cetuximab; lane 3: gefitinib; lane 4: everolimus.
mTOR inhibition in EGFR-drugs-resistant tumours
R Bianco et al
925
British Journal of Cancer (2008) 98(5), 923–930 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sEverolimus inhibits mTOR pathway in resistant cancer
cells
As mTOR signalling is dependent on growth factors, including
EGF, we compared everolimus with gefitinib or cetuximab in both
wild type and EGFR inhibitor-resistant cancer cell lines, focusing
on the mTOR effector p70S6 Kinase. Western Blot analysis
revealed that in wild-type GEO and PC3 cells, everolimus
(0.1mM) reduces p70S6K phosphorylation similarly to gefitinib or
cetuximab, confirming the role of EGFR in mTOR signalling
regulation. In resistant GEO-CR, GEO-GR, PC3-GR and MDA-468
cells, EGFR inhibitors were ineffective on p70S6K activity, whereas
everolimus caused a complete suppression of p70S6K phosphory-
lation (Figure 1D).
Everolimus restores the survival-inhibitory effects of anti-
EGFR drugs in resistant cancer cells
To verify the effects of everolimus alone or in combination with
gefitinib on wild-type GEO and GEO-GR cell lines, we performed a
cell-survival assay. As expected, gefitinib (5mM) induced a 50%
cell-survival inhibition in GEO cells, whereas it was totally
ineffective on GEO-GR cells. Everolimus (0.1mM) was effective on
GEO cells, with a cell-survival inhibition of about 25%, and it
showed a slight activity on GEO-GR cells. Combination of
everolimus and gefitinib improved the cell-survival inhibition
caused by gefitinib alone in sensitive GEO cells, and it partially
reverted the resistance to gefitinib in GEO-GR cells with a cell-
survival inhibition of about 30% (Figure 2A). These results refer to
the simultaneous administration of the two agents. This modality
was chosen because previously we performed a series of
experiments to test different sequences of administration of the
two drugs, comparing either the use of everolimus 1, 6 or 24h
before gefitinib, or gefitinib before everolimus or their simulta-
neous treatment. We observed no significant differences among
the different modalities used (data not shown).
As Akt is involved in pathways regulating cell survival, we
investigated the effect of the combined treatment with everolimus
and gefitinib on Akt phosphorylation/activation. As expected,
gefitinib is able to inhibit Akt activation in GEO, but not in GEO-
GR cells, whereas everolimus has no effect on Akt phosphorylation
in both cell lines (Figure 2B). Conversely, the combination of
everolimus and gefitinib strongly reduces pAkt levels, to a greater
extent in GEO-GR than in GEO cells (Figure 2B).
Everolimus reduces the secretion of VEGF in wild type and
resistant cancer cells
Based on the reported ability of mTOR to affect VEGF levels (Guba
et al, 2002), we evaluated the effect of everolimus on VEGF
production in our cancer cell lines. As shown in Figure 3A,
everolimus reduces human VEGF (hVEGF) secretion of 20–45%
both in wild type and in resistant cell lines, compared with
untreated controls. We then measured hVEGF by ELISA assay on
conditioned media derived from GEO and GEO-GR cancer cell
culture treated for 24h with everolimus (0.1mM) and gefitinib
(5mM) alone or in combination. Gefitinib significantly reduces
hVEGF levels only in wild-type GEO cells, whereas everolimus is
active in both cell lines, especially in resistant GEO-GR cells.
Combined treatment with gefitinib and everolimus causes a strong
reduction of hVEGF levels both in GEO and in GEO-GR cells
(Figure 3B and C).
Everolimus inhibits vascular endothelial cells proliferation
and VEGF-mediated angiogenesis
Based on evidence that the mTOR-p70S6K signalling pathway is
required for VEGF stimulation of endothelial cells (Yu and Sato,
1999), we verified whether everolimus could inhibit angiogenesis at a
second level, where receptor-mediated stimulation of vascular
endothelial cells occurs. To investigate this hypothesis, we first
evaluated the capability of everolimus to inhibit HUVECs (human
umbilical vein endothelial cells) survival: HUVECs are sensitive to
everolimus, with a 35% survival inhibition at 0.1mM (Figure 3D). As
shown in Figure 3E, combined treatment with everolimus (0.01mM)
and gefitinib (1mM) caused a 50% inhibition of HUVEC survival, with
a cooperative effect compared with the single agents. We then
examined the effects of everolimus on VEGF-stimulated capillary tube
and network formation, and we found that this process is inhibited by
everolimus 0.1mM, by gefitinib 5mM and almost suppressed by the
combination of the two drugs (Figure 3F). Thus, VEGF-dependent
HUVEC proliferation and tube formation seem to be very sensitive to
everolimus and gefitinib inhibition.
Combination of everolimus with gefitinib cooperatively
inhibits GEO and GEO-GR colon cancer xenografts growth
To further investigate the role of everolimus on cancer cells
resistant to EGFR inhibitors, we established GEO and GEO-GR
xenografts by using BalbC nude mice. As expected, treatment with
gefitinib alone was effective on GEO xenografts, but ineffective on
GEO-GR xenografts, because, on day 56, all mice in this group
reached the maximum allowed tumour size of about 2cm
3.
Conversely, treatment with everolimus produced a 50% tumour
growth inhibition, with an average tumour size of about 1.0cm
3 at
the same time point in both xenograft models. The combination of
everolimus and gefitinib caused a cooperative antitumour activity,
resulting in over 90% tumour growth inhibition on day 56 (tumour
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Figure 2 (A) GEO and GEO-GR cells were treated with everolimus
(0.1mM) or gefitinib (5mM) alone or in combination. The results are
statistically significant for everolimus plus gefitinib vs control, vs everolimus
alone and vs gefitinib alone (two-sided Po0.0001). For GEO cells, the
results are statistically significant for both gefitinib and everolimus vs control
(two-sided Po0.0001), whereas for GEO-GR cells only for everolimus vs
control (two-sided Po0.0001). (B) Western blotting on total cell lysates
from GEO and GEO-GR cells treated with 1mM gefitinib and/or 0.1mM
everolimus. Lane 1: untreated control; lane 2: gefitinib; lane 3: everolimus;
lane 4: gefitinib plus everolimus.
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3) not only in GEO, but also in GEO-GR-
xenografted mice (Figure 4A and B). At the end of the experiment, 10
weeks after treatment withdrawal, GEO-GR tumour growth inhibi-
tion was still evident and tumour size was about 1cm
3 (Figure 4B).
Comparison of tumour sizes among different treatment groups,
evaluated by the Student’s t-test, was statistically significant.
The treatment with gefitinib alone prolonged strongly the
survival of GEO-xenografted mice (about 20% of mice were still
alive at the end of the experiment), but no significant gain of
survival was observed for GEO-GR-xenografted mice, compared
with untreated animals. Mice treated with everolimus alone
reached the tumour size of about 2cm
3 13–14 weeks after tumour
injection, with a median gain in survival compared with untreated
animals of 5 weeks in GEO-xenografted mice and 7 weeks in GEO-
GR mice. Combined treatment with everolimus and gefitinib
produced a dramatic survival prolongation not only in GEO but
also in GEO-GR-xenografted mice, in fact at the end of the
experiment, 80% of mice were still alive (Figure 4C and D).
Differences among the groups were calculated by log-rank test. No
treatment-related side effects were observed in the treated mice.
Combination of everolimus and gefitinib inhibits the
expression of signalling proteins in GEO-GR xenografts
We analysed the effect of treatment on the expression of a variety
of proteins having a critical role in cancer cell proliferation and
angiogenesis. Western blotting analysis was performed on cell
lysates from tumours removed at the end of the third week of
treatment, on day 25. Everolimus markedly reduced mTOR
effector phospho-p70S6K in GEO-GR xenografts, whereas gefitinib,
as expected, was ineffective. The combination of everolimus with
gefitinib caused a complete suppression of p70S6K phosphoryla-
tion/activation. When used alone, gefitinib and everolimus
produced only a slight reduction of activity of EGFR effectors
Akt and MAPK; in addition, the combined treatment efficiently
reduced phopsho-Akt and phospho-MAPK expression without
affecting the total amount of p70S6K, Akt and MAPK. Finally,
gefitinib did not modify VEGF expression, whereas everolimus
alone caused a moderate VEGF reduction further improved by the
addition of gefitinib (Figure 5A).
Combination of everolimus and gefitinib reduces the levels
of hVEGF, but not of murine VEGF, in GEO-GR tumour
specimens and in mice serum
To further investigate the effect of treatment on VEGF levels, we
performed ELISA assays on protein extracts from tumour speci-
mens and on serum derived from GEO-GR xenografts. Treatment
with gefitinib caused only a slight reduction of both intratumour
and circulating hVEGF levels, whereas everolimus treatment
reduces hVEGF of about 25% both in tumour specimens and in
serum. Combined treatment with everolimus and gefitinib induces
a more potent inhibition of hVEGF levels as compared with
treatment with single agents (Figure 5B and C). Conversely, neither
single agent nor their combination affects murine VEGF (mVEGF)
as compared with untreated mice (data not shown).
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Figure 3 ELISA assays for hVEGF on conditioned media from (A) cancer cells treated with everolimus (0.1mM) and from (B) GEO and (C) GEO-GR
cancer cells treated with everolimus (0.1mM) and gefitinib (5mM) alone or in combination. HUVEC cells were treated with everolimus from 1nM to 1mM (D)
or with everolimus 0.01mM and gefitinib 1mM alone or the combination (E). HUVECs were incubated on solidified matrigel in presence of everolimus 0.1mM,
gefitinib 5mM or the combination. The positive control was matrigel with VEGF 100ngml
 1. Photographies were performed at 0 and 24h (F). All the results
are statistically significant for each treatment vs control (two-sided Po0.0001).
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In the past few years, we have learned that rational combination of
targeted therapeutics may achieve a more potent antitumour effect
and help to overcome the development of resistance, an emerging
clinical issue often responsible for the failure of most modern
antitumour approaches. In the case of EGFR and mTOR signalling
pathways, many experimental data suggest that these pathways
share overlapping signalling outputs (Adjei, 2006). Moreover,
continued activation of PI3K/Akt signalling, which triggers mTOR,
seems to contribute to the development and maintenance of an
EGFR-resistant phenotype (Chakravarti et al, 2002; Vivanco and
Sawyers, 2002; Bianco et al, 2003; Janmaat et al, 2003), and it has
been found in tumour samples from cancers patients failed in
EGFR-targeted therapy (Rojo et al, 2006). These evidences support
the hypothesis that a more efficient antitumour effect may result
from the combined blockade of EGFR and mTOR signalling
pathways. Preclinical evidences demonstrate that this approach
may be particularly effective, at least in some experimental models
in which the combination of EGFR antagonists, such as gefitinib or
erlotinib, and mTOR inhibitors, such as rapamycin and ever-
olimus, resulted in an enhanced tumour cell growth control
(Gemmill et al, 2005; Goudar et al, 2005; Rao et al, 2005; Wang
et al, 2006; Jimeno et al, 2007). Recently, a pilot study including 28
heavily pretreated patients with recurrent malignant gliomas
treated with the combination of gefitinib or erlotinib and
rapamycin reported interesting results in terms of toxicity and
tumour response (Doherty et al, 2006).
In the present study, we demonstrated that blocking mTOR
activity might induce inhibition of cancer cell proliferation and
survival. Interestingly, the antiproliferative effect exerted by the
specific mTOR inhibitor everolimus does not strictly rely on the
integrity of an EGFR-driven signal transduction pathway. In fact,
everolimus is not only effective in tumour cells with acquired
resistance to anti-EGFR drugs, but it is also able to induce a re-
sensitisation against this class of inhibitors. In our experimental
model, constitutive activation of the mTOR target p70S6K, which
may be phosphorylated by Akt-dependent and Akt-independent
mechanisms, invariably correlates with lack of response to EGFR
antagonists. In addition, mTOR targeting by the specific inhibitor
everolimus not only results in significant antiproliferative activity
but also restores sensitivity to anti-EGFR drugs in resistant cancer
cells, producing a strong reduction of Akt activation, when used in
combination with anti-EGFR drugs. Although sequence has been
reported to be important in some papers, in this study, we have
chosen the simultaneous administration of everolimus and anti-
EGFR drugs as treatment modality, because a series of experiments
showed no significant differences compared with sequential
administration.
It is known that inhibition of mTOR pathway correlates with
decreasing of angiogenesis: in fact, rapamycin is able to reduce
tumour vascularisation by promoting endothelial cell death and
inducing increased susceptibility of tumour-specific vessels to
thrombosis (Guba et al, 2005). Moreover, mTOR inhibition
improves the antiangiogenic activity of anti-VEGF antibody
(Stephan et al, 2004). It has also been clearly demonstrated that
rapamycin impaires VEGF production and secretion in human
cancer cells in vitro and endogenous VEGF in serum derived from
mice bearing human tumours (Guba et al, 2002). These preclinical
data have been confirmed by recently reported clinical data with
temsirolimus in combination with antiangiogenic agents. In a phase
I trial in patients with measurable stage IV clear cell renal cell
carcinoma, combination therapy with temsirolimus and bevacizu-
mab was safe and showed promising clinical antitumour activity
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Figure 4 (A and B) After 7 days following tumour injection, 10 mice were treated. Tumour sizes among different treatment groups at day 56 following
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s(Merchan, 2007). A phase I study of temsirolimus in combination
with sorafenib in patients with advanced solid malignancies also
produced good results, without the evidence of drug–drug
interactions (Patnaik, 2007). Interestingly, although EGFR inhibition
induces a VEGF reduction in both protein extracts and conditioned
media of wild-type tumour cells, only everolimus efficiently inhibits
VEGF levels in EGFR inhibitor-resistant cells. Moreover, we have
shown that the antiangiogenic effect of everolimus correlates not
only with the reduction of VEGF by cancer cells but also with a
direct inhibitory effect on endothelial cells, as proven by its ability to
inhibit HUVEC proliferation and tubular formation alone and in
combination with gefitinib.
The combined treatment with gefitinib and everolimus potenti-
ates antitumour and antiangiogenic effects also in mice bearing GEO
and GEO-GR xenografts, in which we observed a cooperative
antitumour activity resulting in over 90% tumour growth inhibition
on day 56, a dramatic survival prolongation; these effects correlate
with a potent inhibition of Akt activation and with a serum
reduction of hVEGF but not of mVEGF. The antiangiogenic activity
of an EGFR and mTOR combined inhibition has been reported by
others. Jimeno and co-workers (Jimeno et al, 2007) demonstrated
that the combination of temsirolimus and erlotinib results in a
synergistic antitumour effect against squamous cell carcinoma cell
lines, sensitive or resistant to EGFR inhibitors.
In conclusion, mTOR inhibition causes antitumour activity in
EGFR-resistant cancer cell lines and xenografts, and this effect
seems to be mediated by inhibition of survival signalling pathways
and angiogenesis. The combination of everolimus with an EGFR
inhibitor potentiates this effect, and it may resensitise resistant
cancer cells to EGFR antagonists. In light of the recent approval of
mTOR inhibitors, these results support the clinical development of
anti-EGFR and mTOR drugs in combination.
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